北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
One-Year Outcomes from an All-Comers Chinese Population of Patients Implanted With the Resolute Zotarolimus-Eluting Stent
作者: Qiao, Shubin1; Chen, Lianglong2; Chen, Shaoliang3; Wang, Weimin4; Zhu, Guoying5
刊名: AMERICAN JOURNAL OF CARDIOLOGY
发表日期: 2014-02-15
DOI: 10.1016/j.amjcard.2013.10.042
卷: 113, 期:4, 页:613-620
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems
研究领域[WOS]: Cardiovascular System & Cardiology
关键词[WOS]: PERCUTANEOUS CORONARY INTERVENTIONS ; ANTIPLATELET THERAPY ; TASK-FORCE ; TRIALS ; SAFETY ; DEFINITIONS ; GUIDELINES ; CARDIOLOGY ; REGISTRY ; SOCIETY
英文摘要:

The RESOLUTE China Registry is a prospective, multicenter, all-corners, observational study of patients in China implanted with the Resolute zotarolimus-eluting stent (R-ZES). R-ZES was commercially available before the enrollment began. All patients suitable for R-ZES implantation according to applicable guidelines were candidates for enrollment at 30 centers and were treated per standard hospital practice. Dual antiplatelet therapy (DAFT) was prescribed for a minimum of 6 months per current European Society of Cardiology guidelines and the device instructions for use. There were 1,800 patients enrolled with a mean age of 61.3 +/- 10.9 years, 76% of patients were men, and 61% had complex disease. DAPT use was 94% at 1 year. Target lesion failure (cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization) at 1 year was 3.5% (95% confidence interval 2.7% to 4.5%). The rate of cardiac death was 0.6%, target vessel myocardial infarction 2.3%, and clinically driven target lesion revascularization 0.9%. The 1-year rate of definite or probable stent thrombosis was 0.5% (8 of 1,750); 0.4% (7 of 1,750) occurred early (0 to 30 days) and 1 event occurred late (1 to 12 months). One stent thrombosis occurred in a patient who had an interruption of DAPT within the first month; all other stent thromboses occurred while on DAFT. Outcomes did not differ significantly between monitored and unmonitored patients (difference in target lesion failure, p = 0.264). In conclusion, the RESOLUTE China Registry confirms the safety and effectiveness of R-ZES in a large real-world Chinese population. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved.

语种: 英语
项目资助者: Medtronic Inc., Shanghai, China
WOS记录号: WOS:000331772800007
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/59688
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Wuhan Asia Heart Hosp, Wuhan, Hubei, Peoples R China
2.Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China
3.Nanjing First Hosp, Jiangshu, Peoples R China
4.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
5.Beijing Fu Wai Hosp, Beijing, Peoples R China

Recommended Citation:
Qiao, Shubin,Chen, Lianglong,Chen, Shaoliang,et al. One-Year Outcomes from an All-Comers Chinese Population of Patients Implanted With the Resolute Zotarolimus-Eluting Stent[J]. AMERICAN JOURNAL OF CARDIOLOGY,2014,113(4):613-620.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Qiao, Shubin]'s Articles
[Chen, Lianglong]'s Articles
[Chen, Shaoliang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Qiao, Shubin]‘s Articles
[Chen, Lianglong]‘s Articles
[Chen, Shaoliang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace